Insights into Company Bills & Payments

Nocil Limited

📍 Mumbai, Maharashtra, India Active NSE NOCIL CIN L99999MH1961PLC012003
Search companies

Key Metrics of Nocil Limited

Revenue₹1,303 Cr▼ 6.4% YoYFY 2025-26
EBITDA₹139 Cr▼ 19.9% YoY
Net profit₹64.1 Cr▼ 40.4% YoY
Net worth₹1,773 Cr▲ 1.1% YoY

About Nocil Limited

Company details

Registered office
Mafatlal House, H T Parekh Marg, Backbay Reclamation, Churchgate, Mumbai, In-mh, 400020
Listed
NSE: NOCIL · ₹146.70

Company summary

Entity details

CINL99999MH1961PLC012003
LEI code335800E78TMI5P232Q87
State codeMH
PIN code400020
Current legal nameNOCIL LIMITED
Classification—
Listing statusListed (NSE: NOCIL)
Registration no.012003
Company age—
PAN—
CountryIndia
CityMumbai
StateMaharashtra
Current statusActive
Date of incorporation—
Registrar of companies—
Authorised capital—
Paid-up capital—
Employee count—

Compliance

Last AGM date—
Last balance sheet—
Next filing dueAOC-4 for FY 2025-26 · 30 Oct 2026

Industry classification

NIC code99999
Description of main activityExtra-territorial organisations and bodies
Description of business activityExtra-territorial organisations and bodies
SectorOther Industries · Discovered Companies

Share price · NSE: NOCIL

NOCIL on NSE

Premium

Financials, ratios and risk analysis

Revenue, EBITDA, net profit, net worth, debt and assets for every filing year, 15+ ratios, the financial health score, shareholding, charges and peer comparison are part of the premium plan.

Sign in to continue See plans & pricing

Filing compliance

AGM for FY 2025-2630 Sep 2026 Statutory due date passed
AOC-4 for FY 2025-2630 Oct 2026 Statutory due date · 1 days left
MGT-7 for FY 2025-2629 Nov 2026 Statutory due date · 31 days left

Due dates follow the Companies Act: AGM within six months of the year end, AOC-4 within 30 days and MGT-7 within 60 days of the AGM. A filing made but not yet uploaded here shows as pending.

Vendor checks & payment capacity

Sign in with access to company financials to review vendor evidence.

Credit ratings

CARE · 03 Oct 2025 CARE AA Stable outlook · Short term A1+ · Reaffirmed
Change in last 12 monthsNo change
Change since first rating on recordNo changesince Mar 2019
Rating actions90 up · 0 down
Liquidity (CARE)Strong

Rating history

Rating actions

DateAgencyActionLong termShort termOutlookRated amountRationale
03 Oct 2025CAREReaffirmed AAA1+Stable₹700 Cr View
26 Dec 2024CAREOther ———— View
09 Oct 2023CAREOther ———— View
30 Aug 2022CAREReaffirmed AAA1+Stable₹500 Cr View
04 Jan 2022CAREReaffirmed AAA1+Stable₹200 Cr View
05 Jan 2021CAREReaffirmed AAA1+Stable₹400 Cr View
09 Mar 2020CAREReaffirmed AAA1+Stable₹400 Cr View
12 Mar 2019CAREReaffirmed AAA1+Stable₹200 Cr View
06 Mar 2019CAREOther ———— View

Credit strengths (CARE, Oct 2025)

+ Leadership position in the domestic rubber chemicals industry

NOCIL has over four decades of experience in manufacturing rubber chemicals. Over the years, it maintained a leadership position in the domestic rubber chemicals market with a product portfolio comprising over 20+ rubber chemicals. The company has an estimated market share of ~40% in the domestic rubber chemicals industry. Furthermore, the company has a presence in over 40 countries and enjoys long -standing relationships with its customers.

+ Liquidity: Strong

NOCIL’s liquidity continues to remain strong, marked by nil term debt repayment obligations in the near term, unutilised fund- based limits of ₹150 crore and healthy cash and liquid investments of ₹208 crore (excluding investments of ₹65 crore in unquoted FD) as on March 31, 2025. The company utilisesits non-based limits in the form of BG for procurement of raw materials, utilisation of which stood minimal at 2.65% in the last twelve months ended July 31, 2025. The company’s liquidity is further

Credit challenges

− Moderation in operating performance in FY25 and Q1FY26

NOCIL’s total operating income (TOI) declined by ~4% year-on-year (y-o-y) to ₹1392 crore in FY25, primarily due to a 9% y-o- y decline in overall realisations considering dumping led pricing pressure. Decline in revenue was partially offset by volume growth of 5% y-o-y, supported by strong growth of 12% y-o-y in export sales. Domestic volumes witnessed a modest growth of 2% y- o-y due to dumping from China, South Korea, Thailand and EU. Domestic sales contributed 64% to the total revenue in FY25

− Competition from cheap imports

NOCIL faces competitive pressure from dumping of rubber chemicals in the Indian market, mainly from China, South Korea, Thailand and EU. Being a major producer of rubber chemicals in the world, China contributes significantly to the global exports. Chinese and other Asian manufacturers benefit from lower production costs and economies of scale, leading to pricing pressure and reduced margins for domestic producers. Amidst large imports, the company has been maintaining competitive pricing to

− Profitability exposed to raw material price volatility

Most of NOCIL’s raw materials including benzene, chlorinated aromatics, and amines among others, are predominantly crude derivatives. Thus, raw material price volatility has a bearing on NOCIL’s profitability margins. NOCIL usually enters fixed-price volume contracts, for a quarter, with key customers, while remaining customers are contracted on a spot basis. There has been a declining trend in raw material prices for the company. However, higher decline in finished product prices, on the back o

− High dependence on automobile and tyre industry resulting in sector concentration risk

The automobile industry is the major consumer of rubber and rubber chemicals for manufacturing tyres and other auto components. It constitutes ~70-80% of rubber chemicals demand. NOCIL’s revenue thus remains exposed to performance of automobile and tyre industry. CareEdge Ratings expects stable domestic demand prospects for rubber chemicals, primarily backed 2 CARE Ratings Ltd. Press Release by stable demand prospects for tyres aided by replacement demand. Furthermore, recent reduction of GST ra

Could lead to an upgrade

• Substantial increase in global market share backed by improved exports, resulting in more diversified operations. • Sustained improvement in profit before interest, lease rentals, depreciation, and taxation (PBILDT) margin at more than 25%, while maintaining strong capital structure and

Could lead to a downgrade

• Significant reliance on debt for funding of growth plans leading to moderation in net debt/PBILDT beyond 1x on a sustained basis. • Changes in government regulations pertaining to production and sales of certain products, significantly impacting its business and profitability.

Agency-reported financials (CARE, 03 Oct 2025)

MetricQ1FY26
Total operating income₹336 Cr
PBILDT₹30.58 Cr
PAT₹17.26 Cr
Overall gearing (times)—
Interest coverage (times)82.65×
EBITDA margin9.1%
Implied interest cost (EBITDA ÷ coverage)₹0.37 Cr
PAT margin5.1%

Borrowings & rated debt

Rated borrowing limits (latest)₹700 Cr
Peak rated limits₹700 CrOct 2025 · CARE
Limits raised0 times1 new facility rated

Rated limits over time

Facility mix

Rated facilities

FacilityTypePreviousCurrentChangeRatingActionAgency
Long-term bank facilitiesWorking capital & bank lines—₹100 Cr— AA (Stable)AssignedCARE
Long-term bank facilitiesWorking capital & bank lines—₹175 Cr— AA (Stable)ReaffirmedCARE
Short-term bank facilitiesWorking capital & bank lines—₹425 Cr— A1+ReaffirmedCARE

CARE ratings on record (checked 23 Oct 2026)

InstrumentAmountRating
BG/LC₹425 CrCARE A1+
Commercial Paper (Carved out)—Withdrawn
Long Term₹175 CrCARE AA; Stable
Term Loan—Withdrawn
Term Loan₹100 CrCARE AA; Stable

Lenders

Fund-basedLong TermAxis Bank Ltd.
Fund-basedLong TermHDFC Bank Ltd.
Fund-basedLong TermICICI Bank Ltd.
Fund-basedLong TermIDFC First Bank Ltd.
Fund-basedLong TermProposed
Fund-based - LTTerm LoanProposed
Non-fund-based - STBG/LCAxis Bank Ltd.
Non-fund-based - STBG/LCCitibank N A
Non-fund-based - STBG/LCHDFC Bank Ltd.
Non-fund-based - STBG/LCICICI Bank Ltd.
Non-fund-based - STBG/LCIDFC First Bank Ltd.

Credit assessment · Manufacturing

Rating Methodology – Manufacturing Companies (Mar 2025) · Standalone accounts · FY 2025-26

Indicative long-term—
Indicative short-term—
Score—
LiquidityAdequateAgency: Strong
DirectionStableAgency outlook: Stable
CARE rating · Oct 2025AA1 notch above indicative

Ratios, pillar scores and the indicative rating are part of Premium.

Rating status

DefaultNo default on record
Issuer cooperationCooperating
Credit enhancementNone – standalone rating
Next action stable or better (model)83%
Information on file78% · missing: Capex / investment plans, Auditor details

Indicative assessment from public data using the published methodology factors; not a credit rating.

Borrowing & funding lifecycle

⬇ PDF report⬇ Excel
Can it borrow more?Further bank funding likely Next rating action stable or better: 83% (Stable or improving) · ML model on 4072 rating histories, AUC 0.666
Rated limits₹700 Cr
Not yet allocated—
Extra debt within 3.5× EBITDA—
Interest coverage82.65×
Limit utilisation—
Open bank charges0 · —
  • Credit outlook model: 83% chance the next rating action is stable or better
  • Current rating AA (investment grade)
  • Interest coverage 82.65×

Rated limits by facility

Timeline

03 Oct 2025 CARE reaffirmed: AA (Stable)Rated limits ₹700 cr CARE rationale
03 Oct 2025 Cash & liquid funds ₹208 cr, undrawn lines ₹150 cr
From the report

Liquidity: Strong NOCIL’s liquidity continues to remain strong, marked by nil term debt repayment obligations in the near term, unutilised fund- based limits of ₹150 crore and healthy cash and liquid investments of ₹208 crore (excluding investments of ₹65 crore in unquoted FD) as on March 31, 2025.

CARE rationale
26 Dec 2024 CARE other: — CARE rationale
26 Dec 2024 Cash & liquid funds ₹372 cr, undrawn lines ₹150 cr
From the report

Liquidity: Strong NOCIL’s strong liquidity is marked by unutilised fund based working capital limits of ₹150 crore and healthy free cash & liquid investments of ₹372 crore as on September 30, 2024.

CARE rationale
26 Dec 2024 Average working-capital utilisation 10%
From the report

NOCIL hardly utilises fund-based working capital limits, while average utilisation of non-fund-based limits stood minimal at ~10% in 12-months ended July 2024.

CARE rationale
09 Oct 2023 CARE other: — CARE rationale
30 Aug 2022 CARE reaffirmed: AA (Stable)Rated limits ₹500 cr CARE rationale
04 Jan 2022 CARE reaffirmed: AA (Stable)Rated limits ₹200 cr CARE rationale
05 Jan 2021 CARE reaffirmed: AA (Stable)Rated limits ₹400 cr CARE rationale
09 Mar 2020 CARE reaffirmed: AA (Stable)Rated limits ₹400 cr CARE rationale
12 Mar 2019 CARE reaffirmed: AA (Stable)Rated limits ₹200 cr CARE rationale
06 Mar 2019 CARE other: — CARE rationale

Lender names, bank charges and audited borrowings are part of Premium.

Built from MCA charges, ICRA/CARE rating reports and audited accounts. The borrowing view is an estimate, not a lender's credit decision.

Registered office and contact

Registered officeMAFATLAL HOUSE, H T PAREKH MARG, BACKBAY RECLAMATION, CHURCHGATE, MUMBAI, IN-MH, 400020
GSTIN—
Email—
Website—
Members / shareholders—

Directors and key people

Directors are read from the MGT-7 annual return and AOC-4 signatories.

Charges (secured borrowings)

0 registered charges. Lenders, amounts and dates are part of the premium plan.

Statutory auditors

Auditors are read from the AOC-4 auditor's report section.

Business activities and related parties

Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.

Filings

No filings on record yet.